title: Clinical aspects and prognosis of ependymoma in infants and children. A single institution experience.
abstract: Thirty-two patients (22 boys and 10 girls) with a histologically confirmed diagnosis of ependymoma were treated between 1972 and 1999. A total macroscopic resection was achieved in 16 of these patients, whereas 15 resections were classified by the surgeon as subtotal. In 1 patient a ventriculostomy was created as part of a palliative strategy. All children over 3 years old were treated with postoperative radiotherapy. Chemotherapy consisted of procarbazine, ifosfamide, etoposide, methotrexate, cisplatin and cytosine arabinoside. There was 1 perioperative death. Twenty children developed a relapse of disease within 2 months to 13 years and 1 month after the initial therapy. A maximal number of five recurrences were seen in 1 patient. The value of adjuvant chemotherapy on the prognosis of children with ependymoma seems to be limited. With regard to the poor outcome, the advisability of further treatment after multiple recurrences is debatable.
authors.affiliation: Department of Pediatrics, University of Mainz, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Humpl
authors.forename: H
authors.initials: H
authors.lastname: Neuser
authors.forename: K
authors.initials: K
authors.lastname: Brühl
authors.forename: U
authors.initials: U
authors.lastname: Bartels
authors.forename: M
authors.initials: M
authors.lastname: Schwarz
authors.forename: P
authors.initials: P
authors.lastname: Gutjahr
mesh_terms: D000293:Adolescent; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004806:Ependymoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D016896:Treatment Outcome